Beremans Ltd Announces Publication of Cardiotoxicity Report in Collaboration With Insight Pharma Reports (Cambridge Healthtech Institute)

Posted by admin

April 21, 2008

CAMBRIDGE, England, April 21 /PRNewswire/ — Beremans Ltd (http://www.beremans.com), a Cambridge (UK)-basedcompany that provides business intelligence services for the Life Sciencessector, announced today the publication of a report covering issues relatedto cardiotoxicity and drug development. The report discusses methods,products and services designed to identify cardiotoxic compounds before theyreach the market; discusses the current and possible future regulatoryenvironment; outlines main commercial competitors; and suggests broad typesof commercial opportunity in this subsector. The primary focus is onidentification of drug-induced proarrhythmia, but some discussion is providedon identification of other forms of cardiotoxicity. In particular, the report compares various recommended andproposed surrogates for torsades de pointes (TdP) risk. Preclinical andclinical proarrhythmia screens are discussed, including in silico methods, invitro single cell / multicellular methods, in vivo methods and early clinicaltrial methods. Some discussion also is provided on mechanisms of screeningfor ‘direct’ (non-proarrhythmic) cardiotoxicity. In addition, the reportcontains the results of an industry survey undertaken by online questionnaireand by one-to-one interviews with key experts. An overview of 50 commercialentities offering cardiotoxicity screening products / services is provided.Further analysis is included regarding the competitive positioning andownership of 29 companies that have some clear cardiotoxicity screeningfocus. Broad consolidation / M&A opportunities are outlined in general terms.Finally, the report provides a subjective opinion on the future ofcardiotoxicity screening, suggests how regulatory guidelines might change inthe future, and outlines some commercial opportunities that might beassociated with the current / future cardiotoxicity screening environment. Dr. Nicholas Miller, MD of Beremans Ltd, said “CHI / InsightPharma were aware of work previously carried out by Beremans in the field ofcardiotoxicity screening, and contacted us to discuss collaborating on anup-to-date analysis of the technical state of the art and the commercial /regulatory environment pertinent to this complex field. We were delighted toparticipate, as this is the type of analysis at which Beremans excels.Furthermore, it speaks to some of the core areas of focus in Beremans,including high-throughput screening.”Beremans Limited

Biotechonology